Market Research Blog

Hospitals to hold largest share in Ultrasound Systems Market with highest demand for application in Radiology

Hospitals shift toward more value-oriented products, they need to operate more efficiently and productively. Similarly, a quality shift has occurred with patients, who more proactively involved in their care. Trends from the shift to value-based care include data integration and population health management. An influx of data combined with advancements in imaging helps leverage these data to not only bring further value but also apply it to broader populations. Along with the clearer and high definition pictures that are a part of ultrasound systems, there has also been an introduction to the portable machines. These are the more handy and easy to move form of ultrasound systems that have come into existence not long ago. Although the developed nations are already familiar with the technology, the market may find a higher prospects of growth in the developing regions. The market analysis has shown that hospitals hold the highest market share in the Global Ultrasound Systems Market, however diagnostics imaging and surgical centers are expected to raise a higher demand for the systems in the coming years. In terms of application the market is also dominated by Radiology as the key application area for ultrasound systems and is expected to continue growing further at a CAGR of 6.3% during the forecast period, as analyzed by FMI.

To remain ‘ahead’ of your competitors, request for a sample

Favourable Government Policies to Benefit Start-up Companies and Independent diagnostic centers

As a move to encourage start-up companies, government of various regions like Asia Pacific and MEA have bolstered the initiatives to support the new start-ups who are entering the healthcare and medical device industry. It includes exemption of taxes for the first three years, subsidizing patent protection cost etc. The move is intended to boost the overall market for medical devices. Specifically the medical imaging market has also taken an independent position in the global market. With the betterment in services and advanced facilities related to ultrasound or any other imaging techniques, the global market is expected to witness a higher volume of independent imaging centers. The companies have also independently introduced handy and user-friendly devices in the market. GE, Philips, Samsung, Fukuda, Mindray, Hitachi, Toshiba, and Siemens, all these companies offer their own particular models.

The coming years will showcase more advanced ultrasound systems, which will provide an image clearer than 3D or 4D pictures.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6695

Market Taxonomy

By Modality

• Cart/Trolley Based
• Compact/Handheld Ultrasound Devices

By Application

• Radiology
• Obstetrics and Gynecology
• Gastroenterology
• Cardiovascular
• Others (Breast Imaging, Urology, Emergency Care and among others)

By End User

• Hospitals & Clinics
• Diagnostic Imaging & Surgical Centers
• ASCs
• Others

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• MEA

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/6695

Key Takeaways – Laparoscopic Devices Market Study

• Steady demand growth is observed for bariatric surgery, in line with the expanding obese population coupled with wide-scale adoption rate of minimally invasive techniques. Sales of laparoscopic devices for bariatric surgery will surpassing that for colorectal surgery towards the end of projection period.

• Sales of laparoscopic devices will be higher in North American countries. The availability of skilled surgeons and several advantages of minimally invasive surgery over open surgery are few factors driving the market of laparoscopy devices.

• The key players in the laparoscopic devices market are focusing on technologically advanced surgical systems with improved dexterity, ergonomics, and visual enhancements that provide advantages to surgeons and minimize the risk for patients while undergoing laparoscopic procedures.

• Increasing consumer base along with modern amenities in the healthcare sector is expected to drive sales of laparoscopic devices in developing regions.

Rising private and foreign investments in the laparoscopic devices market and adoption of subscription commerce marketing model by market players are anticipated to shape the overall laparoscopic devices market.

To remain ‘ahead’ of your competitors, request for a sample

Growing Popularity of Single-incision Laparoscopic Surgery

Single-site incisional surgery is being widely used in laparoscopic procedures and is replacing traditional method of laparoscopic procedures, in which four to five small incisions were made as the entry point for laparoscopic instruments. Some of the key benefits of single-site incision laparoscopic procedure over traditional procedure are low chances of infections, better cosmetic results, quick recovery and less post-operative pain.

According to Journal of the Society of Laparoendoscopic Surgeons (JSLS), women who undergo single-site incision laparoscopic surgery tend to report lesser post-operative pain compared to traditional method laparoscopic surgery. Growing demand for single-incision laparoscopic surgeries would thus drive the growth of laparoscopic devices market.

Adoption of Subscription Commerce Marketing Model

Companies are adopting various marketing model schemes such as subscription commerce to boost the sale of laparoscopic devices. Under this scheme, companies provide medical devices such as laparoscopy devices on pay-per-use basis. Thus, various end use segments can have access to these devices which might otherwise be prohibitively expensive, which in turn is helping manufacturers to expand their market share for laparoscopic devices, globally.

Due to intense competition, manufacturers of laparoscopic devices use innovative pricing strategies to remain at the forefront. Expanding access of laparoscopic devices by educating healthcare professionals through various conferences and training is enabling companies manufacturing these devices to enhance the adoption and equipping healthcare facilities with the necessary tools to provide optimal care to patients.

Interested in More About Report Inclusions?

Laparoscopic Devices Market, a new study from Future Market Insights, opines on the evolution of the laparoscopic devices market from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of product type (direct energy system devices, trocars/access device, internal closure devices, laparoscopes, hand access instruments, insufflation devices, and robotic assisted surgical system), therapeutic application (bariatric surgery, colorectal surgery, general surgery, gynecological surgery and urological surgery), and end user (hospitals, ambulatory surgical centers, and clinics) across seven major regions.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-497

LAPAROSCOPIC DEVICES MARKET TAXONOMY

The global laparoscopic devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product

• Direct Energy System Devices
• Trocars/Access Devices
• Internal Closure Devices
• Laparoscopes
• Hand Access Instruments
• Insufflation Devices
• Robotic Assisted Surgical System

Therapeutic Application

• Bariatric Surgery
• Colorectal Surgery
• General Surgery
• Gynecological Surgery
• Urological Surgery

End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-497

Regions

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan (APEJ)
• Japan
• Middle East and Africa (MEA)

Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population. Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.

To remain ‘ahead’ of your competitors, request for a sample 

For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are

• Valeant Pharmaceuticals International Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Mylan N.V.
• Abbott Laboratories
• GlaxoSmithKline Plc.
• Dr. Reddy’s Laboratories Ltd.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Doctors are stepping up their efforts by creating awareness among the patients with regard to benefits of anti-inflammatory drugs, which have been deemed effective in the prevention and control of rare inflammatory diseases. Currently, there is rapid increase in the demand for authorized effective treatments of the rare inflammatory diseases. The OOPD (Office of Orphan Products Development) has been offering incentives to drug companies, supporting the development of treatment methods for these diseases. National Institutes of Health (NIH) are providing immense support for improving patients’ health, by focusing mainly on the development of new treatment methods. Collaborative projects are being initiated by NIH in order to examine the common causes and effects of related diseases.

Significant findings from report show that the global market for rare inflammatory disease treatment will increase at an assessed 4.4% CAGR during the forecast period, 2017-2026. The report also anticipates that by 2026-end, rare inflammatory disease treatment worth nearly US$ 15,960.8Mn will be witnessed across the globe.

Increasing Inflammatory & Autoimmune Diseases to Create Opportunities for New Therapies

Several group of scientists have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases, which in turn is creating new ways of development for therapies. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.

Moreover, the occurrence of inflammatory and autoimmune diseases is increasing on a rapid pace. Globally, an approximate number of 125 million populace are affected by psoriasis and around 100 million by rheumatoid arthritis annually. The presence of inflammatory bowel infections such as ulcerative colitis and Crohn’s disease is increasing at an alarming rate in formerly unaffected fragments of the world.

To remain ‘ahead’ of your competitors, request for a sample

Key Takeaways from Rare Inflammatory Disease Treatment Market Report for Estimated Period, 2017-2026

• In terms of revenue, North America will remain the largest market for rare inflammatory disease treatment market, closely followed by Europe. Nearly half value share of the market is held by rare inflammatory disease treatment sales in North America and Europe collectively. APEJ will also bolt onto a largest market revenue share, by registering a relatively faster expansion than Europe in the market through 2026.

• On the basis of indication, ulcerative colitis are likely to remain considerably larger than that of the other segments.

• The lion’s share in the global market for rare inflammatory disease treatment is contributed by biologics segment.

• Oral care & Hospital Pharmacies will observe fastest growth during the forecast period.

Key market players outlined by the report is inclusive of

• Pfizer, Inc.
• Allergan Plc
• Valeant
• Johnson & Johnson
• Questcor Pharmaceuticals, Inc.
• Novartis AG
• Abbvie
• Abbott Laboratories
• Regeneron Pharmaceuticals
• Swedish Orphan Biovitrum AB.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6428

Market Taxonomy

For meeting the objectives of the findings, the global rare inflammatory disease treatment market report has been segmented based on the distribution channel, drug class, mode of administration, indication, and region. As per the taxonomy detailed in the report, global market for rare inflammatory diseases treatment has been listed accordingly:

Region

• North America
• Latin America
• Europe
• Japan
• APEJ
• MEA

Indication

• Ulcerative Colitis
• Juvenile Rheumatoid Arthritis
• Psoriatic Arthritis
• Other Indications

Drug Class

• Biologics
• Organic Compounds

Mode of Administration

• Injectables
• Oral
• Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-6428

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Various leading market players are focusing on collaborative product development that has led to product innovation and availability of therapeutic options. For instance, GSK Consumer Healthcare has been established under single business following the completion of the merger of the consumer arms of GSK and Pfizer on August 1 in 2020

Rapidly growing ageing populations and rising prevalence of obesity expected to create considerable growth opportunities. The anti-osteoporosis therapy and fracture healing market is expected to grow significantly in terms of revenue over the forecast period owing to the increase in the availability of technologically advanced products options all over the world.

Moreover, stringent regulations are key restraints affecting growth of anti-osteoporosis therapy and fracture healing market. Side effects caused by osteoporosis drugs such as mild to fatal nausea, skin rashes, and others could affect growth of the market. Stringent regulations imposed by international organizations such as the U.S. Food and Drug Administration, which also conducts frequent revisions of side effects for osteoporosis drugs are challenging anti-osteoporosis therapy and fracture healing market growth.

To remain ‘ahead’ of your competitors, request for a sample

Key Takeaways from Anti-osteoporosis Therapy and Fracture Healing Market Study

Anti-osteoporosis therapy and fracture healing market is expected to register 4.5% Y-o-Y growth in 2021

The demand from the U.S. is expected to be considerably, enabling it to account for a little below 90% of the North America market

The U.K. market is expected to register 5.4% Y-o-Y growth in 2021

France and Germany are likely to exhibit considerably high demand for anti-osteoporosis therapy and fracture healing

Within East Asia, both Japan and South Korea will emerge as key markets

“Increasing prevalence of osteoporosis and rising number of road accidents have fuelled the demand for minimally invasive therapeutics, which is sees as a key market driver. Market players are currently focusing on expanding their distribution channels to strengthen their footprint within the market, while hospital pharmacies continue to remain their preferred channel,” a lead FMI analyst.

Product Launches Remain Key Strategy

Product approvals by the U. S. FDA for anti-osteoporosis therapy and fracture healing drugs as well as injectable are expected to push towards high competition among market players. Numerous companies are focusing on advanced product development that is convenient to use and provide rapid efficacy in the treatment of osteoporosis.

For Instance, in April 2019, Amgen Inc. announced about approval of its EVENITY® by U.S. Food and Drug Administration (FDA) used in the treatment of postmenopausal women at high risk for fracture. According to FMI, oral drugs will continue accounting for the leading market share. Oral will remain highly preferred as route of drug administration, accounting for over 64% of the market in 2021.

Who is winning?

The global market is set to broaden its scope in the forecast period, stimulated by high prevalence rate of osteoporosis, rising geriatric population globally and adoption of advanced anti-osteoporosis therapy and fracture healing products which can be used for long term care needs. In addition to this, changing regulatory dynamics and patent expiry of blockbuster drugs has constrained the sales of anti-osteoporosis therapy and fracture healing products.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1008

The key market players covered by FMI include

• Eli Lilly and Company
• Pfizer, Inc.
• Amgen Inc.
• Merck and Company Inc.
• Novartis International AG
• F. Hoffmann La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline Plc.

consolidating their positions through mergers, acquisitions and new product launches.